A Step Toward the Development of the First National Multi-CriteriaDecision Analysis Framework to Support Healthcare Decision Making inSaudi Arabia

被引:3
作者
Al-Jedai, Ahmed [1 ]
Almudaiheem, Hajer [2 ]
Alruthia, Yazeed [3 ]
Althemery, Abdullah [4 ]
Alabdulkarim, Hana [5 ]
Ojeil, Rita [6 ,11 ]
Alrumaih, Ali [7 ]
Alghannam, Suliman [8 ]
Almutairi, Abdulaali [9 ]
Hasnan, Zuhair [10 ]
机构
[1] Minist Hlth, Therapeut Affairs Support Serv, Riyadh, Saudi Arabia
[2] Minist Hlth, Pharm & Therapeut Comm, Riyadh, Saudi Arabia
[3] King Saud Univ, Coll Pharm, Pharmacoecon, Riyadh, Saudi Arabia
[4] Prince Sattam Bin Abdulaziz Univ, Pharmacoecon, Riyadh, Saudi Arabia
[5] Minist Natl Guard Hlth Affairs, Drug Policy Ctr, Riyadh, Saudi Arabia
[6] Carexso, Market Access & HEOR, Dubai, U Arab Emirates
[7] Prince Sultan Cardiac Ctr, Med Serv Dept, Riyadh, Saudi Arabia
[8] King Abdullah Int Med Res Ctr, Populat Hlth Dept, Riyadh, Saudi Arabia
[9] Saudi Food & Drug Author, Riyadh, Saudi Arabia
[10] King Faisal Specialist Hosp & Res Ctr, Med Genom Dept, Riyadh, Saudi Arabia
[11] Carexso, Market Access & HEOR, Dubai, U Arab Emirates
关键词
health assessment technology; Kingdom of Saudi Arabia; multi -criteria decision analysis; orphan drugs; TECHNOLOGY-ASSESSMENT; ORPHAN DRUGS; MCDA; ACCESS;
D O I
10.1016/j.vhri.2023.12.005
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: To assess the feasibility of implementing multi-criteria decision analysis (MCDA) and to select the criteria for preparing a national MCDA framework for health technology assessment of orphan drugs in the Kingdom of Saudi Arabia Methods: The study was conducted in 3 phases. In phase I, a targeted literature review was performed to gather relevant information on the implementation of MCDA in healthcare decision making. Phase II was a cross-sectional survey, conducted to obtain insights from different stakeholders and key opinion leaders on specific topics from the KSA perspective. Phase III included a round-table discussion involving experts to validate the results obtained in the phase II survey and further elaborate on specific requirements that may be critical for developing the first national MCDA framework in the KSA. Results: All the key opinion leaders involved in the study acknowledged the importance of implementing MCDA in the KSA. The Ministry of Health was assigned the responsibility of chairing the MCDA decision process. The experts selected the quantitative, qualitative, and economic criteria to be considered for the MCDA framework. The stakeholders decided to initiate a pilot phase using the deliberative MCDA methodology for the assessment of orphan drugs based on the selected criteria for a period of 1 year and then reevaluate the need to adapt the pragmatic MCDA model. Conclusion: This article describes the novel initiative that examined the feasibility and process required for the development of the first MCDA framework in the KSA to support healthcare decision making.
引用
收藏
页码:100 / 107
页数:8
相关论文
共 37 条
[1]   The use of pharmacoeconomic evidence to support formulary decision making in Saudi Arabia: Methodological recommendations [J].
AL Aqeel, Sinaa A. ;
Al-Sultan, Mohammed .
SAUDI PHARMACEUTICAL JOURNAL, 2012, 20 (03) :187-194
[2]   Genetic dilsorders in the Arab world [J].
Al-Gazali, Lihadh ;
Hamamy, Hanan ;
Al-Arrayad, Shaikha .
BMJ-BRITISH MEDICAL JOURNAL, 2006, 333 (7573) :831-834B
[3]   Access to orphan drugs in the Middle East: Challenge and perspective [J].
Almalki, Ziyad S. ;
Alahmari, Abdullah K. ;
Guo, Jeff J. ;
Kelton, Christina M. L. .
INTRACTABLE & RARE DISEASES RESEARCH, 2012, 1 (04) :139-143
[4]   Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework [J].
Angelis, Aris ;
Kanavos, Panos .
SOCIAL SCIENCE & MEDICINE, 2017, 188 :137-156
[5]  
[Anonymous], 2020, Vision 2030
[6]  
[Anonymous], 2011, Multiple criteria decision making-from early history to the 21st century
[7]   Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward [J].
Baltussen, Rob ;
Marsh, Kevin ;
Thokala, Praveen ;
Diaby, Vakaramoko ;
Castro, Hector ;
Cleemput, Irina ;
Garau, Martina ;
Iskrov, Georgi ;
Olyaeemanesh, Alireza ;
Mirelman, Andrew ;
Mobinizadeh, Mohammedreza ;
Morton, Alec ;
Tringali, Michele ;
van Til, Janine ;
Valentim, Joice ;
Wagner, Monika ;
Youngkong, Sitaporn ;
Zah, Vladimir ;
Toll, Agnes ;
Jansen, Maarten ;
Bijlmakers, Leon ;
Oortwijn, Wija ;
Broekhuizen, Henk .
VALUE IN HEALTH, 2019, 22 (11) :1283-1288
[8]  
Bana E Costa CA, 2005, INT SER OPER RES MAN, V78, P409, DOI 10.1007/0-387-23081-5_10
[9]   Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs-a Systematic Literature Review. Next Steps in Methodology Development? [J].
Baran-Kooiker, Aleksandra ;
Czech, Marcin ;
Kooiker, Coen .
FRONTIERS IN PUBLIC HEALTH, 2018, 6
[10]  
Belton Valerie., 2002, Multiple Criteria Decision Analysis: An Integrated Approach, DOI 10.1007/978-1-4615-1495-4